However, it is important to note that up to 18 months treatment with azeliragon (small molecule RAGE antagonist targeting the extracellular domains) in older patients with cognitive impairment did not result in the reporting of increased susceptibility to infections or other infectious sequelae [29]. This evidence concerns the gene AGER and infection.